Table 2.
Underlying traits, pre-scan risk factors for CIN and scan characteristics among the 53 patient pairs.
| Both Patients | Neither Patient | Contrast Patient Only | Noncontrast Patient Only |
Contrast Associated Excess (95% CI) | |
|---|---|---|---|---|---|
| Diabetesa | 15 28% |
38 72% |
0 0% |
0 0% |
|
| Ventilated at time of CTa | 22 42% |
31 59% |
0 0% |
0 0% |
|
| Pressor use in 4 hrs before CTa | 2 4% |
51 96% |
0 0% |
0 0% |
|
| Liver Disease | 4 8% |
27 51% |
13 25% |
9 17% |
-10% to 24% |
| CHF (current or Class III/IV) | 2 4% |
41 77% |
3 6% |
7 13% |
-20% to 5% |
| Hypertension | 22 42% |
13 25% |
9 17% |
9 17% |
-16% to 16% |
| New sepsis before scan | 0 0% |
37 70% |
8 15% |
8 15% |
-15% to 15% |
| Nephrotoxin in 3 days pre-scan | 6 11% |
29 55% |
10 19% |
8 15% |
-12% to 19% |
| Trimethoprim/cimetidine pre-scan | 0 0% |
47 89% |
3 6% |
3 6% |
-11% to 11% |
| Body area scanned | |||||
| Head | 10 19% |
12 23% |
9 17% |
22 42% |
-42% to -4% |
| Chest | 14 26% |
10 19% |
21 40% |
8 15% |
5% to 42% |
| Abdomen/pelvis | 7 13% |
23 43% |
20 38% |
3 6% |
15% to 46% |
aMatching criterion. CHF, congestive heart failure; CIN, contrast induced nephropathy; CT, computerized tomography.